Christian Cremer

Title: The Innovations of Christian Cremer

Introduction

Christian Cremer is an accomplished inventor based in Aachen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of human cytolytic fusion proteins. His work focuses on creating novel solutions that can induce apoptosis in human cells, which has important implications for medical research and treatment.

Latest Patents

Christian Cremer holds a patent for "Human cytolytic fusion proteins." This technology relates to innovative human cytolytic fusion proteins (hCFPs) that are designed to induce apoptosis in human cells. The hCFPs comprise a target cell-specific binding component and a human effector domain. The binding component includes an antibody or an antibody fragment that targets the cellular surface receptor CD64. The effector domain consists of a variant of wild type human angiogenin (Ang) or a functional fragment thereof. Additionally, the patent covers nucleic acid molecules encoding these recombinant hCFPs, as well as vectors and host cells containing the nucleic acids, along with methods for their preparation and production.

Career Highlights

Christian Cremer is affiliated with the University of Cape Town, where he continues to advance his research in biotechnology. His innovative work has garnered attention in the scientific community, contributing to the understanding of apoptosis and its applications in medicine.

Collaborations

Throughout his career, Christian has collaborated with notable colleagues, including Stefan Barth and Thomas Nachreiner. These partnerships have enhanced his research efforts and expanded the impact of his inventions.

Conclusion

Christian Cremer's contributions to the field of biotechnology through his patent on human cytolytic fusion proteins exemplify the importance of innovation in medical research. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.